Becton Dickinson stock (US0718131099): SEC filing and recent moves keep NYSE BDX in focus

Becton Dickinson shares on the NYSE traded roughly unchanged on 06/02/2026 as investors digested a recent SEC 8-K filing and earlier insider transactions, while the U.S. medical technology group remains in the spotlight ahead of its next earnings update.

Becton Dickinson shares on the New York Stock Exchange traded roughly flat around the mid-140 USD range on 06/02/2026, as investors weighed a recent U.S. SEC Form 8-K filing from 05/29/2026 and earlier insider activity against the broader healthcare sector backdrop, keeping the U.S.-listed medical technology group in focus according to exchange and filing data from NYSE and the SEC as of 06/02/2026.

The stock, which trades on the NYSE under the ticker BDX and is a component of major U.S. healthcare indices, has seen muted price action in early June, following a period in which its 1-year total shareholder return turned negative even as some valuation models still see upside relative to estimated fair value, according to Simply Wall St as of 05/31/2026.

As of 06/02/2026, NYSE data show Becton Dickinson changing hands in regular trading hours in U.S. dollars without any indication of a corporate delisting or completed take-private transaction, confirming that the United States remains the primary home market and listing venue for the stock.

For German investors, Becton Dickinson is also accessible via secondary trading venues such as Tradegate in euro, where indicative prices typically track the NYSE quotation adjusted for currency, providing an additional access point alongside the U.S. home exchange according to German market data pages as of 06/02/2026.

The latest 8-K from 05/29/2026 references a material event for Becton Dickinson, underscoring the steady flow of regulatory disclosures that investors monitor for updates on operations, financing, or governance, even when no major price reaction is immediately visible in the U.S. market.

The stock’s valuation has drawn attention in recent weeks, with Simply Wall St calculating a fair value estimate of about USD 192.31 per share versus a spot price around USD 147.12 in late May 2026, suggesting the shares were trading at a discount on that model as of 05/31/2026.

From a fund-flow perspective, institutional investors have continued to adjust positions in the name, with one recent filing showing Mawer Investment Management trimming its stake in Becton Dickinson by nearly half in the fourth quarter, illustrating how portfolio managers continue to rebalance exposure to U.S. large-cap healthcare stocks according to MarketBeat as of 06/02/2026.

At the same time, aggregated analyst data indicate that coverage of Becton Dickinson by major banks remains active, with the consensus rating currently in the hold range and an average 12-month price target around USD 183.64 as compiled by MarketBeat from 16 analysts as of late May 2026, suggesting expectations for moderate upside over a one-year horizon without signaling strong conviction in either direction.

The stock traded at approximately USD 147.12 in late May 2026 on the NYSE, according to Simply Wall St quoting exchange data as of 05/31/2026, implying that the consensus target from MarketBeat sits more than 20 percent above that reference level, although both metrics are subject to change as markets and forecasts evolve.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Becton Dickinson
• Sector/industry: Medical technology and diagnostics
• Headquarters/country: Franklin Lakes, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Medical devices, diagnostic systems, and life-science tools
• Home exchange/listing venue: NYSE (BDX)
• Trading currency: USD

Becton Dickinson: core business model

Becton Dickinson focuses on developing and supplying medical devices, diagnostic platforms, and laboratory solutions that support healthcare providers worldwide, with sales largely driven by recurring demand for single-use instruments and equipment used in hospitals, laboratories, and other care settings.

Latest quarterly results for Becton Dickinson at a glance

For its most recently reported quarter, fiscal Q2 2026, Becton Dickinson disclosed consolidated revenue of around USD 5.06 billion, representing a modest year-on-year increase versus the comparable period in the prior fiscal year, according to the company’s latest quarterly earnings release on its investor relations website dated 05/02/2026.

In the same Q2 2026 update, the company reported adjusted earnings per share in the mid-USD 3 range, reflecting stable profitability trends in its core segments, while management reiterated its full-year outlook for both revenue growth and margin performance, according to the 05/02/2026 earnings materials on the Becton Dickinson investor relations site.

Conclusion

Becton Dickinson’s share price on 06/02/2026 reflects a period of consolidation on the NYSE as the market digests a string of regulatory filings and the latest fiscal Q2 2026 earnings figures.

With consensus analyst data pointing to a hold rating and an average target above the current trading range, alongside a fair-value estimate that also sits higher than spot, investors are closely watching whether operational execution and sector conditions will be sufficient to close the perceived valuation gap over time.

Against this backdrop, upcoming earnings updates and any further SEC disclosures will likely play a central role in shaping sentiment toward the United States-based medtech group’s stock trajectory.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.